A Study in Prevention of Re-emergence of Depression Symptoms
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to assess the maintenance of efficacy of LY2216684
compared with placebo as adjunctive therapy to selective serotonin reuptake inhibitors
(SSRIs) as measured by the time-to-symptom reemergence among participants with major
depressive disorder (MDD) who met randomization criteria with adjunctive LY2216684 during the
stabilization period.
This trial consists of two distinct periods: an open-label treatment period, which consists
of two parts, 8 weeks acute open-label with movement to 12 weeks open-label stabilization if
participants are in remission at end of 8 weeks (open-label for 20 weeks total) followed by a
randomized, double-blind, placebo-controlled period for 24 weeks.